Efficacy and safety of lobeglitazone versus sitagliptin as an add‐on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks. Issue 10 (18th June 2020)

• Record Type: Journal Article
• Authors: Kim, Sin Gon; Kim, Kyoung Jin; Yoon, Kun Ho; Chun, Sung Wan; Park, Kyong Soo; Choi, Kyung Mook; Lim, Soo; Mok, Ji‐Oh; Lee, Hyoung Woo; Seo, Ji A.; Cha, Bong‐Soo; Kim, Mi Kyung; Shon, Ho Sang; Choi, Dong Seop; Kim, Doo Man
• Is Part Of: Diabetes, obesity & metabolism. Volume 22:Issue 10(2020)
• Page Start: 1869
• Page End: 1873
• Publication Date: 2020-06-18
• Subjects: clinical trial -- lobeglitazone -- randomized trial -- thiazolidinediones -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14085
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add‐on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between‐group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non‐inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add‐on to metformin in terms of efficacy and safety.